News | May 02, 2026
Bayer pushes stroke prevention drug forward in China as regulators accept key filing
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
The deal, backed by healthcare investor ARCHIMED, signals a major push to accelerate connected, patient-centered cardiac care worldwide
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The agreement could rise to $900 million if key commercial milestones are met
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Subscribe To Our Newsletter & Stay Updated
